Matches in Wikidata for { <http://www.wikidata.org/entity/Q73039402> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- Q73039402 description "artikull shkencor i botuar më 01 shkurt 1997" @default.
- Q73039402 description "artículu científicu espublizáu en febreru de 1997" @default.
- Q73039402 description "im Februar 1997 veröffentlichter wissenschaftlicher Artikel" @default.
- Q73039402 description "scientific article published on 01 February 1997" @default.
- Q73039402 description "wetenschappelijk artikel" @default.
- Q73039402 description "наукова стаття, опублікована в лютому 1997" @default.
- Q73039402 name "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 name "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 name "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 type Item @default.
- Q73039402 label "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 label "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 label "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 prefLabel "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 prefLabel "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 prefLabel "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 P1433 Q73039402-A92963D1-12FF-484E-9B61-FBA6B7EA715C @default.
- Q73039402 P1476 Q73039402-8DA84870-6E7C-4CCC-800B-F28840078B73 @default.
- Q73039402 P2093 Q73039402-1E200825-1F46-42CA-8544-B8CB2809061E @default.
- Q73039402 P2093 Q73039402-2DDB4F73-3EBC-47F6-B214-30DB0C033E99 @default.
- Q73039402 P2093 Q73039402-2EB937FC-70E1-475B-9DE0-37DACBD18CA3 @default.
- Q73039402 P2093 Q73039402-5F483F2E-3552-41E3-9958-2B9B129801D7 @default.
- Q73039402 P2093 Q73039402-7167BBFF-C85B-4099-9051-956700F1474C @default.
- Q73039402 P2093 Q73039402-92544141-B283-4C5E-B4D2-A9DB377F71B7 @default.
- Q73039402 P2093 Q73039402-9A7E734D-38BD-42E8-9271-9483625F75E4 @default.
- Q73039402 P2093 Q73039402-A8E87D7D-64D6-41FC-9EE1-75E7589749D0 @default.
- Q73039402 P2093 Q73039402-B95BF143-9A7D-4A3A-955C-7A8E56204F03 @default.
- Q73039402 P2093 Q73039402-CA2E9CFF-9C76-4514-A505-64115B3BB9D6 @default.
- Q73039402 P2093 Q73039402-DEC6ECCD-13A9-4A76-9233-6EC2440FA223 @default.
- Q73039402 P304 Q73039402-2F104A05-C01F-4753-AA77-E821EA9A7CCB @default.
- Q73039402 P31 Q73039402-A6014BF9-0643-4265-8A74-FFE11DCA2ABB @default.
- Q73039402 P356 Q73039402-ACBBD8D9-70A7-41B7-8253-DB3EFBFD6EF5 @default.
- Q73039402 P407 Q73039402-344372D1-85CC-4336-B359-64A0DCE17E2F @default.
- Q73039402 P433 Q73039402-CEA717D1-A524-4C01-BE70-A92DB8541624 @default.
- Q73039402 P478 Q73039402-AEF8AB9C-3629-4AB1-82A8-CDC76B6D269F @default.
- Q73039402 P577 Q73039402-ED6629D7-97B6-44A3-8A9C-C2D5EEC648FE @default.
- Q73039402 P698 Q73039402-C127D6DF-05CE-436A-A96A-41B10E115370 @default.
- Q73039402 P921 Q73039402-321AD4D2-B759-4479-86C2-D4C6C698C8D5 @default.
- Q73039402 P921 Q73039402-92083F77-6F1B-4C7A-8413-99743F3A67FF @default.
- Q73039402 P921 Q73039402-94F9A904-48CA-4B74-AF8C-C5A31EBC6FBF @default.
- Q73039402 P356 JAMA.277.6.482 @default.
- Q73039402 P698 9020273 @default.
- Q73039402 P1433 Q1470970 @default.
- Q73039402 P1476 "Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group" @default.
- Q73039402 P2093 "A M Fein" @default.
- Q73039402 P2093 "E C Fletcher" @default.
- Q73039402 P2093 "G J Criner" @default.
- Q73039402 P2093 "G M Matuschak" @default.
- Q73039402 P2093 "G R Bernard" @default.
- Q73039402 P2093 "H Levy" @default.
- Q73039402 P2093 "H M Shanies" @default.
- Q73039402 P2093 "J T Good" @default.
- Q73039402 P2093 "R W Taylor" @default.
- Q73039402 P2093 "T C Rodell" @default.
- Q73039402 P2093 "W A Knaus" @default.
- Q73039402 P304 "482-487" @default.
- Q73039402 P31 Q13442814 @default.
- Q73039402 P356 "10.1001/JAMA.277.6.482" @default.
- Q73039402 P407 Q1860 @default.
- Q73039402 P433 "6" @default.
- Q73039402 P478 "277" @default.
- Q73039402 P577 "1997-02-01T00:00:00Z" @default.
- Q73039402 P698 "9020273" @default.
- Q73039402 P921 Q183134 @default.
- Q73039402 P921 Q269829 @default.
- Q73039402 P921 Q776030 @default.